Phase 3 Trial of Once-Weekly SHR-3167 vs Insulin Glargine Registered

A new Phase 3 clinical trial involving insulin glargine was registered on November 6, 2026. The study, titled "Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes," is listed under identifier NCT07920939. The trial is designed to compare once-weekly SHR-3167 against once-daily insulin glargine in adults with insulin-naive type 2 diabetes. According to the registration, the trial status is currently "not yet recruiting." This means participant enrollment has not begun as of the listing date. The study is registered as a Phase 3 trial, a stage typically involving larger patient populations to evaluate efficacy and safety. No results, outcomes, or safety data have been posted for this trial at this time. The trial record does not include information on enrollment numbers, sites, or an estimated completion date. As the trial has not started recruiting, no statements can be made about its findings or progress. Insulin glargine remains an approved medication, and this registration reflects a new comparative study involving the compound. Readers can consult the compound overview for additional context on insulin glargine.